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Phase II Study of Paclitaxel, Carboplatin, and Cetuximab as
First Line Treatment, for Patients with Advanced Non-small
Cell Lung Cancer (NSCLC)
Results of OPN-017
Hossein Borghaei, DO,* Corey J. Langer, MD, FACP,* Michael Millenson, MD,*
Karen J. Ruth, MS,† Samuel Litwin, PhD,† Holly Tuttle, RN, MSN,‡
Judie Sylvester Seldomridge, RN, OCN,‡ Marc Rovito, MD,§ David Mintzer, MD, Roger Cohen,* and
Joseph Treat¶
Background: Cetuximab has demonstrated synergy with taxanes in
preclinical models; as well as single agent activity. We assessed the
activity of cetuximab with carboplatin and paclitaxel given on a
4-week schedule, in advanced, chemo-naive non-small cell lung
cancer.
Patients and Methods: This phase II, single arm, multi-institution
study featured standard dosage of cetuximab 400 mg/m2 day 1, then
250 mg/m2 with paclitaxel (100 mg/m2/wk, for 3 weeks), and
carboplatin (area under curve 6) day 1 of each 28 day cycle. After
4 to 6 cycles, in the absence of disease progression or excess
toxicity, cetuximab was continued weekly. Primary end point was
response rate.
Results: Fifty-three patients (median age 63, 51% male) partici-
pated. Response rate was 57% (3 complete response and 27 partial
response). At a median follow-up of 12.5 months, the estimated
overall survival is 13.8 months (95% CI: 9.08–16.02) with an
event-free survival rate of 5.53 months (95% CI: 4.77–7.99), 18.9%
remain free from progression at 1 year. Improved survival was
associated with female gender, absence of prior radiation, PS 0 and
epidermal growth factor receptor expression. Toxicities included
rash (28% grade 3), nail changes (3.7% grade 3), hypomagnesemia
(7.5% grade 3 and 3.7% grade 4), and neutropenia (25% grade 3 and
13% grade 4) in addition to other typical side effects anticipated
with paclitaxel/carboplatin. There were no grade 5 toxicities.
Conclusion: Combination of cetuximab/paclitaxel/carboplatin in
non-small cell lung cancer was well tolerated and clinically active
with manageable toxicities. This unique schedule, integrating
weekly paclitaxel and cetuximab has not yet been tested in a
randomized trial.
Key Words: Non-small cell lung cancer, Cetuximab, Immunother-
apy, Chemotherapy.
(J Thorac Oncol. 2008;3: 1286–1292)
Monoclonal antibodies are major therapeutic agents inthe treatment of malignant disease, and combination
antibody and chemotherapy has become a standard approach
in the management of many solid and hematologic malignan-
cies.1,2 Lung cancer is the second most common cancer
diagnosed for both genders in the United States, with approx-
imately 213,380 new cases estimated in 2007, and prognosis
remains generally poor for patients with advanced disease.
The addition of bevacizumab to standard chemotherapy with
carboplatin and paclitaxel was shown to improve overall
survival of patients with incurable nonsquamous lung cancer
in the front-line setting.3 However, many patients are not
appropriate for bevacizumab, including patients with squa-
mous histology, current use of anticoagulation, antecedent
hemoptysis, or prior brain metastasis.
Epidermal growth factor receptor (EGFR) is another
potential, “exploitable” target for the treatment of non-small
cell lung cancer (NSCLC). Patients with NSCLC expressing
high levels of ErbB1 have more aggressive disease and an
unfavorable prognosis.4 Studies of single-agent erlotinib in
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incurable NSCLC have shown favorable effects on survival
(BR.21) leading to Food and Drug Administration registra-
tion in the second and third-line setting.5 Cetuximab, a
humanized, IgG1 mAb, recognizes the EGFR extracellular
domain and competes for ligand binding to the receptor,
representing an alternative approach to EGFR targeting.6,7 A
recently completed randomized trial of carboplatin and pac-
litaxel every 3 weeks with cetuximab in patients with ad-
vanced lung cancer concluded that the regimen was well-
tolerated and active.8
There is preclinical evidence for cytotoxic synergy
between cetuximab and both platinum and paclitaxel.9 The
study reported here was designed to maximize the therapeutic
index10 and thus employed monthly carboplatin and pacli-
taxel on days 1, 8, and 15, along with cetuximab weekly. In
addition, it was felt that weekly paclitaxel, as opposed to
standard dosing at 3-week intervals, would help reduce the
incidence of paclitaxel’s nonhematologic toxicity, including
sensory neuropathy and myalgias/arthralgias.
PATIENTS AND METHODS
Study Design
This multicenter, phase II, open label, nonrandomized
study in patients with stage IIIB/IV NSCLC was designed to
determine the efficacy of first line treatment with a combina-
tion regimen of paclitaxel, carboplatin, and cetuximab. Effi-
cacy parameters included response rate (RR), stable disease
rate, time to disease progression, overall survival and toxic-
ity. Patients received six 4-week cycles of cytotoxic therapy.
Cetuximab was administered at an initial dose of 400 mg/m2
IV day 1 of the first cycle, followed by weekly doses of 250
mg/m2. Paclitaxel 100 mg/m2/wk was administered days 1, 8,
and 15 of each 28-day cycle, with carboplatin area under
curve  6 (C-G) added on day 1. The sequence of drug
administration was cetuximab, followed by paclitaxel, and
then carboplatin. Standard premedications and antiemetics
were administered. Patients with CR, partial response (PR),
or SD after 4 to 6 cycles of therapy had the option of
continuing cetuximab therapy (250 mg/m2/wk) until disease
progression, unacceptable toxicity or patient refusal. Patients
who could not tolerate chemotherapy due to toxicity could
continue on cetuximab monotherapy.
Toxicity and Response Monitoring
Toxicities related to the study drugs and dose modifi-
cations were managed according to the established guidelines
for each drug. Worst toxicity grades per patient were tabu-
lated for selected adverse events and laboratory measure-
ments. Adverse events that were serious or resulted in pre-
mature and permanent discontinuation of any study drug were
described in detail. Adverse events and other symptoms were
graded according to the National Cancer Institute, Common
Terminology Criteria for Adverse Events, Version 3.0.
Patients were evaluated for response according to Re-
sponse Evaluation Criteria in Solid Tumors criteria. All
patients receiving any treatment were considered evaluable
for response, except for patients with the wrong cancer
diagnosis. All patients were considered evaluable for safety if
they received any treatment. Response confirmation occurred
4 weeks after criteria for response were met. Patients who
completed therapy, in the absence of progression, were fol-
lowed every 90 days with clinical, laboratory, and radio-
graphic exams until they started new therapy.
Eligibility Criteria
All patients had histologically or cytologically docu-
mented stage IV or IIIB NSCLC (with documented malignant
pleural or pericardial effusion) or recurrent NSCLC after
either primary surgery or radiation. Patients could not have
received any prior systemic chemotherapy for the treatment
of NSCLC, including adjuvant chemotherapy. Measurable
disease and Eastern Cooperative Oncology Group (ECOG)
performance status of 0–1 was required. Patients with asymp-
tomatic brain metastasis were eligible, provided they had
completed radiotherapy at least 2 weeks before enrollment
and were off corticosteroids. Any radiotherapy must have
been completed more than 2 weeks before enrollment, with
recovery from all adverse effects. No previous irradiation was
allowed to the only area of measurable disease except for
unequivocal new lesions that developed in a previously irra-
diated area. Adequate organ function was defined as absolute
neutrophil count 1500/mm3 and platelets 100,000/mm3;
total bilirubin 1.5  upper limit of normal; aspartate
transaminase and alanine aminotransferase 2.5  upper
limit of normal; and serum creatinine 1.5 mg/dl or creati-
nine clearance 50 ml/min if serum creatinine was 1.5.
Patients with tissue available had testing for EGFR expres-
sion by immunohistochemistry. All patients signed an insti-
tutional review board -approved informed consent for this
protocol.
Exclusion criteria included history of prior malignancy,
except for adequately treated basal or squamous cell skin
cancer, in situ cervical cancer, or other cancer for which the
patient had been disease-free for at least 3 years; a significant
history of cardiac disease;. uncontrolled seizure disorder;
active neurologic disease or symptomatic brain metastasis;
prior cetuximab or other therapy that specifically targeted the
EGF pathway; known hypersensitivity to Cremophor EL; and
grade 1 peripheral neuropathy.
Statistics and Sample Size Determination
This single-arm phase II study recruited 53 patients
from Fox Chase Cancer Center and its network partners. The
primary end point of this single-stage study was RR for the
combined regimen. The planned study size of 50 was deter-
mined to distinguish a targeted RR of 35% from the historical
control of 20%, based on ECOG 1594.11 Secondary endpoints
included clinical benefit (defined as rate of complete and
partial remission [CR and PR] and stable disease [SD]),
survival and event-free survival (EFS). Analyses included all
treated patients.
Survival was calculated from start of treatment to date
of death; EFS was calculated from start of treatment to date
of documented disease progression or death in the absence of
progression. Survival and EFS outcomes were censored if an
end point was not reached or if the patient was lost to
follow-up, using date of last follow-up and date of last tumor
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assessment, respectively. Median and 12-month survival,
EFS estimates, and 95%CIs were calculated using the
Kaplan-Meier product-limit method. The effects of baseline
factors on survival and EFS were examined using the logrank
test.
Assessment and Follow-Up
Baseline history and physical examination including
ECOG PS, height, and weight were obtained on all patients.
The physical examination was repeated at the start of every
chemotherapy cycle. Tumor response was assessed every 8
weeks (Q 2 cycles). All patients who received at least one
dose of cetuximab were considered assessable for response.
During the trial, and for 4 weeks after the last dose of
cetuximab, patients were monitored for adverse events. Bio-
chemistry and hematology laboratory assessments were per-
formed at baseline and on day 1 of each cycle (every 28
days). Weekly CBC was obtained before each dose of che-
motherapy. During maintenance therapy with cetuximab,
chemistries, including magnesium, and CBC were obtained
monthly.
RESULTS
Patient Demographics
Table 1 lists patient demographics for this trial. Be-
tween March 2005 and May 2006, 53 patients were accrued
at FCCC and its Partners affiliates. Fifty-one percent of the
patients were male. Median age was 63 years (range, 41–86);
19 patients (36%) were over age 70. Forty-seven percent had
ECOG PS-0; 8% had received prior RT, 11% had treated
brain metastases, and 96% (51 patients) had stage IV or
recurrent disease.
Best Response
The overall confirmed RR by intention to treat was 57%
(3 CR and 27 PR). Twelve additional patients (23%) had
stable disease for an overall disease control rate of 80%. One
patient was not evaluable due to brain metastasis at the time
of diagnosis (Tables 4 and 5).
Survival Estimates
With a median follow-up time of 12.5 months, median
overall survival for the entire group (Figure 1), based on
intention-to-treat analysis, was 13.8 months (95% CI: 9.08–
16.02). One and 2 year survival rates were 52.8% (95% CI:
38.6–65.2) and 18.1% (95% CI: 6.4–64.6), respectively.
Median EFS was 5.53 months (95% CI: 4.77–7.99) with
18.9% free from progression at 1 year (Figure 2). Of 53
patients on the study, 37 died during the study period and 16
were censored as of the last date of analysis. Five patients
remain without disease progression with a median follow-up
time of 13.6 months (range, 12.4–16.1 month) as of the time
of this writing.
Overall Survival by Groups
Table 2 summarizes overall survival and EFS data for
different patient subgroups. Female patients had better over-
all survival (median survival 16 months; 95% CI 14.1–20.3)
compared with males (median survival 7.6 months; 95% CI
5.7–11, logrank p 0.003). In the subset of patients who had
received prior radiation therapy (n  7), the overall survival
was 6 months versus 14 months in those who had not
received radiation (p  0.005). ECOG PS 1 was also an
adverse prognostic indicator; with an overall survival of 7.4
months versus 16 months in PS 0 patients (p  0.01).
Event-free survival followed a similar pattern to overall
survival: 9.6 months for females versus 5.1 month for males,
3.5 months for patients with prior radiation versus 5.7 months
for patients without, 4.6 months for PS 1 patients versus 9.3
months for PS 0. Age, however, had no impact on survival in
TABLE 1. Demographics
n  53 Median Range
Age 63 41–86
Number Percent
Age group
70 34 64
70 19 36
PS
0 25 47
1 28 53
Female 26 49
Male 27 51
Stage
IIIB 2 3.7
IV 51 96.3
Brain mets
No 47 89
Yes 6 11
Prior XRT
Yesa 7 13
No 46 87
Race
White 45 85
AA 6 11
Hispanic 1 2
Asian 1 2
Histology
Adeno 33 62
Squamous 6 11
BAC 2 4
NOS 12 23
EGFR status
Unknown 10 19
Negative 4 8
Insufficient 12 23
Positive
(NOS)b
5 9
1 6 11
2 6 11
3 10 19
aFive patients with prior whole brain irradiation, 2 with lung or bone radiation.
bPositive NOS: Positive EGFR staining but no grading was assigned. BAC,
bronchioloalveolar carcinoma.
XRT, radiation; AA, African American, Mets, metastatic disease, PS, performance
status.
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this analysis. The median survival was similar across all age
groups, including 19 patients over the age of 70. Other
potential prognostic factors such as weight loss were not
routinely determined at baseline.
Survival and EGFR Status
Table 1, lists the EGFR status of patients involved in
this trial. EGFR status was determined by immunohistochem-
istry, as routinely done by the pathology departments of the
participating institutions. Of 31 patients whose EGFR status
was known, 4 were negative. With a median follow-up of
12.5 months, patients with any positive EGFR expression had
a better median survival (14 months versus 6 months) com-
pared with patients with negative EGFR (Table 2). Median
disease- free survival was 6.2 months for any positive EGFR
expression versus 3.5 months without EGFR expression.
Toxicity and Treatment Duration
The median number of chemotherapy cycles adminis-
tered was four. Twenty patients (38%) received 6 cycles and
34 patients (64%) completed at least four. Of 53 patients on
this trial, 15 (28%) went onto maintenance therapy with
single agent cetuximab, 1 after 4 cycles and 14 after 6 cycles
of chemotherapy. The remainder of patients went off study
either due to disease progression before cycle 4 (14 patients,
37%) or due to other causes including toxicity. Median
number of maintenance cycles administered was 5; (range,
1–12); each cycle was defined as 4 weekly infusions of
cetuximab.
The most common reason for study termination was
disease progression (22 patients or 42%). Toxicity was the
second most common reason, in 11 patients or 20% (Table 6).
Toxicities
In general, toxicities were consistent with those antic-
ipated for this regimen (Table 3). The most common attrib-
utable grade 3 and 4 toxicities included neutropenia and nail
and skin changes. Four patients developed DVTs including 4
reported cases of pulmonary embolism; these were felt to be
related to the disease and not the study drugs (Table 3).
Other grade 3 and 4 nonhematologic toxicities included
hypomagnesemia (7.5% grade 3; 3.7% grade 4) and fatigue
(15% grade 3, no grade 4). Five patients (9%) developed
grade 3 sensory neuropathy related to paclitaxel. Grade 1 and
2 dry-cracked skin and nail changes were reported in 21
(40%) and 12 (23%) patients, respectively. These latter skin
toxicities were attributed to cetuximab and persisted for the
duration of cetuximab administration in most patients. The
skin toxicities were managed with Clindamycin gel and
Minocyclin.
Overall 20 patients (37.7%) experienced grade 3 or 4
neutropenia (Table 3). Three patients also developed grade 3
thrombocytopenia. Nine patients suffered minor infections
with grade 1 and 2 neutropenia, and 20 had infections without
neutropenia. These infections were recorded as a result of
meticulous follow-up of patients for adverse events. There
were no neutropenic fevers with grade 3 or 4 neutropenia.
Nor were there any grade 5 toxicities.
Toxicities During Maintenance Therapy
Predominantly grade 2 toxicities (46% rash, 46% xe-
roderma/fissures, 54% nail changes, and 31% sensory neu-
ropathy) were observed for the 13 patients who received
maintenance therapy. There were no grade 4 and only 2
(15%) grade 3 hypomagnesemias during this phase of treat-
ment. Single-agent cetuximab was generally well tolerated
although several patients stopped maintenance treatment be-
cause of persistent, distressing skin and nail toxicity.
DISCUSSION
The primary goals of therapy for patients with Stage IV
NSCLC are to increase survival time, palliate symptoms, and
improve quality of life. Meta-analyses of trials comparing
best supportive care to chemotherapy have shown a survival
benefit for chemotherapy along with symptom improvement,
weight gain, and improvement in performance status.12–14
Nevertheless, survival gains have been modest, and toxicity
continues to be a problem with most doublet regimens.
FIGURE 1. With a median follow-up time of 12.5 months,
median overall survival for the entire group, based on inten-
tion-to-treat analysis, was 13.8 months (95% CI:
9.08–16.02). One year survival was 52.8%.
FIGURE 2. Median event-free survival (time to disease pro-
gression or death in the absence of progression) was 5.53
months (95% CI: 4.77–7.99) with 18.9% free from progres-
sion at 1 year.
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As shown in this report, paclitaxel and cetuximab given
on a weekly schedule, combined with carboplatin once a
month, yields a well-tolerated and active regimen. Our non-
randomized phase 2 trial in a “nonmolecularly selected”
patient population surpassed its primary efficacy end point,
yielding a median overall survival of 13.8 months, among the
highest reported in stage IV disease. It bests any prior efforts
of the FCCC or its network.15,16 Five patients have ongoing
responses as of the time of this report with a median fol-
low-up of 13.6 months.
Most of the toxicities in this study were grade 1–2;
there were no grade 5 toxicities. Skin and nail toxicities were the
most challenging aspect of the management of our patients, in
TABLE 6. Reasons for Treatment Termination
Reason Number Percent
HSR 2 4
PD 22 42
Dermatologic 5 9
MD choice 5 9
Patient choice 2 4
PS decline 4 8
Intercurrent morbiditiesa 5 9
Toxicities 8 15
Toxicities: 3 neurotoxicity, 1 multiple dose reduction, 2 neutropenia, 2 multiple
toxicities.
aOne abscess, 1 MI, 1 ITP, 1 initiation of radiation (in absence of disease
progression) and 1 with prolonged hospitalization.
HSR, hypersensitivity reaction; PD, progressive disease; TOX, toxicities; MD,
physician decision; PS, deterioration of performance status.
TABLE 2. Survival by Subgroup Analysis
Subgroups (no) Median OS (mo) Logrank p Median EFS (mo) Logrank p 1 yr OS (%) 1 yr EFS (%)
Female (26) 16.1 0.003 9.6 0.0002 76.9 38.5
Males (27) 7.6 5.1 29.6 0
PS 0 (25) 16.0 0.02 9.4 0.003 72.0 32.0
PS 1 (28) 7.4 4.6 35.7 7.1
Prior XRT (7) 6.3 0.003 3.5 0.002 14.3 0
No prior XRT (46) 14.1 5.8 58.7 21.7
Age 70 yr (34) 12.2 0.70 6.0 0.84 50.0 17.7
Age 70 yr (19) 14.4 5.4 57.9 21.1
EGFR Pos (27) 14.1 0.03 6.2 0.02 63.0 18.5
EGFR neg (4) 6.1 3.5 25.0 0.0
Rash (15) 20.4 0.072 11.2 0.012 66.7 33.3
No rash (38) 10.8 5.3 47.4 13.2
For the EGFR analysis only the samples with known status were included.
For analysis by rash, patients with grade 3 rash were considered as positive versus others.
XRT, radiation therapy; PS, performance status.
TABLE 3. Selected Grade 3 and 4 Toxicities
Toxicity Grade 3 (percent) Grade 4 (percent)
Fatigue 8 (15.1) 0
Rash 15 (28.3) 0
Nail changes 2 (3.8) 0
Pruritus 2 (3.8) 0
Vomiting 3 (5.7) 0
Diarrhea 3 (5.7) 1 (1.9)
Sensory neuropathy 5 (9.4) 0
Hypomagnesemia 4 (7.5) 2 (3.8)
Dehydration 2 (3.8) 0
DVT 2 (3.8) 1 (1.9)
Pulmonary embolus 1 (1.9) 3 (5.7)
HSR 1 (1.9) 2 (3.8)
WBC 9 (17.0) 2 (3.7)
ANC 13 (24.5) 7 (13.2)
HGB 2 (3.8) 0
PLT 3 (5.7) 0
HSR, hypersensitivity reaction; WBC, white blood cells; HGB, hemoglobin; ANC,
absolute neutrophil count; PLT, platelets.
TABLE 4. Best Response
Response Number Percent
CR 3 6
PR 27 51
SD 12 22
PD 2 4
NA 9 17
TABLE 5. Best Response by Gender
Female (n  26) Male (n  27)
Response Number Percent Number Percent
CR 2 8 1 4
PR 14 54 13 48
SD 5 19 7 26
PD 1 4 1 4
NA 4 15 5 19
Differences in response by gender were not statistically significant, Fisher exact test
p  0.94.
CR, complete response; PR, partial response; SD, stable disease; PD, progression of
disease; NA, taken off treatment prior to first assessment due to toxicity or co-morbidity.
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part because they persisted throughout the course of therapy.
Patient tolerance for acute self-limited toxicities may be
higher than their tolerance for prolonged lower-grade toxic-
ities of the type observed here. Importantly, patients receiving
maintenance cetuximab did not experience significant added
toxicities. The number of patients who went on to receive
single-agent cetuximab was too small, however, to determine
if it improves overall or EFS. The role of maintenance will
require phase III testing.
Subgroup analysis suggests that patients who had re-
ceived prior radiation therapy (whole brain or other regions)
had a worse overall and EFS. Reasons for this difference are
not immediately apparent, but this observation is hypothesis-
generating and suggests that prior RT should be considered a
stratification factor in subsequent studies employing this or
other C225-combinations. The majority (5) of these previ-
ously irradiated patients had received whole brain irradiation.
Central nervous system metastasis is an established poor
prognostic factor for survival. Female patients fared better
compared to males, confirming observations in other studies.
Our study also confirms that patients with better performance
status (0 versus 1) have improved 1-year overall and EFS
(Table 2). The benefits of this therapy were seen across all
age groups. Smoking history was not a variable in determin-
ing response or survival, as only 3 patients on this study were
nonsmokers. Nor was age.
We also showed a correlation between improvement in
median survival and EGFR expression. Pooling the data for all
patients with any positive EGFR expression, median survival
was 14 months in EGFR positive patients versus 6 months for
EGFR negative patients (n  4) (logrank p  0.02) The
numbers are small, but nonetheless intriguing. They argue for
potential patient selection and/or stratification based on tumor
EGFR status in future trials with cetuximab.
How do these data compare with similar recently re-
ported studies? In a study of weekly cetuximab plus every
3-week paclitaxel and carboplatin (n 31) an overall disease
control rate of 65% (39% stable disease, 26% CR and PR)
was reported.17 All patients with a response had 3 EGFR
tumor expression. With a median follow-up of 19 months, the
median time to progression was 5 months, median survival
was 11 months, and the 1- and 2-year survival rates were 40%
and 16%, respectively. Cetuximab in combination with car-
boplatin and gemcitabine in chemo-naive patients (n  35)
with EGFR positive stage IV NSCLC gave similar results
with 10 partial responses (28.6%).18 Twenty one additional
patients had stable disease. The median time to progression
was 5.5 months, and the median overall survival was 10.3
months.
In a preliminary report of a completed randomized
phase II trial comparing the same 4 week cycle of carbopla-
tin, paclitaxel and cetuximab used in our study with the
3-week cycle of the same regimen19 the authors reported a
disease control (CR  PR  SD) rate of 66% in the 3-week
cycle arm versus 62.8% in the 4-week arm. The median
overall survival in the 4-week cycle arm was 10.2 months.
The results of our effort seem superior to those observed in
this randomized phase II study. There is no obvious expla-
nation for the difference; patient selection and tumor EGFR
status are key considerations.
Our data suggest an advantage for concurrent cetux-
imab with a platinating-doublet. Other reports provide a
mixed picture. Lynch et al. at World Conference on Lung
Cancer in 2007 reported the preliminary results of a phase III
trial comparing chemotherapy alone (paclitaxel and carbo-
platin) to chemotherapy  cetuximab in treatment naive
patients, showing an increase in RR, but no significant im-
provement in PFS20 based on external radiographic review.
Likewise, an ASCO 2007 update of a Southwest Oncology
Group study comparing concurrent to sequential cetuximab
suggested little difference in outcome.8 Patient selection
could be one reason for the observed difference between our
trial and others. Also, the synergism between paclitaxel and
cetuximab given on a weekly basis could account for the
reported differences. Future larger trials are needed to answer
this question. The impetus to explore the role of cetuximab in
combination with standard cytotoxic therapy has been further
triggered by the statistically significant survival advantage
observed in the FLEX trial,21 for cetuximab in combination
with vinorelbine and cisplatin versus chemotherapy alone.
This benefit, though modest, was more pronounced in the
cohort of non-Asian enrolled on FLEX.
We have shown that a standard platin doublet and
cetuximab is well tolerated with preliminary promising effi-
cacy data. The result is noteworthy because to date, small
molecule EGFR inhibitors added to standard chemotherapy
regimens for NSCLC have not improved overall or progres-
sion free survival22–25 There are some differences in the
mechanism of action between antibodies and tyrosine kinase
inhibitors that could underlie differential efficacy when com-
bined with chemotherapy. These include (1) interactions with
the immune system, Antibody Dependent Cellular Cytotox-
icity), (2) the ability of antibodies to clear the cell surface of
EGFR, and (3) inhibition of ligand binding to the receptor
versus simple inhibition of the receptor tyrosine kinase. To
determine if antibodies perform better than tyrosine kinase
inhibitors in combination with chemotherapy for the treat-
ment of patients with advanced NSCLC will require results
from ongoing and planned randomized phase 2 and 3 studies.
The results of our trial provide ample justification for further
evaluation of this weekly triplet regimen.
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